caa a22 4500 477057268 CHVBK 20180405111349.0 cr unu---uuuuu 170330e19960601xx s 000 0 eng 10.1007/s002280050107 doi (NATIONALLICENCE)springer-10.1007/s002280050107 Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism [Elektronische Daten] [A. Grove, L. C. McFarlane, C. M. Jackson, B. J. Lipworth] Objectives: Novel assays have been developed for markers of type 1 collagen turnover. The aim of this study was to evaluate the effect of short-term exposure to inhaled corticosteroids on both the novel and conventional markers of bone metabolism. Methods: Nine healthy subjects received 2 weeks treatment with inhaled budesonide 800 μg per day in week 1, and 1600 μg per day in week 2, or fluticasone 750 μg per day in week 1 and 1500 μg per day in week 2, with a 1-week washout in between. Measurement of carboxy-terminal propeptide of type 1 collagen (PICP), carboxy-terminal telopeptide of type 1 collagen (ICTP), plasma alkaline phosphatase bone isoenzyme, and 24-h urinary calcium excretion were made at baseline and at the end of each 2-week treatment period. Results: ICTP was significantly reduced following treatment with budesonide but not fluticasone compared with baseline: baseline 4.2 μg⋅1−1 budesonide 3.0 μg⋅1−1, fluticasone 3.6 μg⋅1−1. There were no significant changes in PICP compared with baseline after treatment with budesonide or fluticasone. The ratio of PICP:ICTP increased significantly after treatment with both budesonide and fluticasone compared with baseline: baseline 27.4, budesonide 43.7, t 42.6. There were no significant differences between the two treatments for any of the measured parameters. Conclusions: Thus, when using sensitive markers of collagen turnover, short-term inhaled corticosteroid therapy was found paradoxically to reduced bone resorption. Springer-Verlag Berlin Heidelberg, 1996 Key words Budesonide nationallicence Fluticasone nationallicence inhaled corticosteroids nationallicence collagen metabolism nationallicence bone metabolism nationallicence Grove A. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut McFarlane L. C. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut Jackson C. M. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut Lipworth B. J. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut https://doi.org/10.1007/s002280050107 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050107 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Grove A. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut NATIONALLICENCE 700 1- McFarlane L. C. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut NATIONALLICENCE 700 1- Jackson C. M. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut NATIONALLICENCE 700 1- Lipworth B. J. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 95Y, UK, GB aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer